Preprint
Viraemia and HIV drug resistance among people receiving dolutegravir versus efavirenz-based first-line antiretroviral therapy
- Abstract:
-
Limited data exists to inform management of viraemia among people receiving dolutegravir-based first-line ART in low- and middle-income countries. Among South-Africans with viraemia ≥1000copies/mL receiving dolutegravir (n=43) and efavirenz (n=37), we found no dolutegravir resistance, but high efavirenz resistance (66.7%). 12-week resuppression was higher with dolutegravir (85%) versus efavirenz (38%).
- Publication status:
- Published
- Peer review status:
- Not peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Pre-print, pdf, 62.9KB, Terms of use)
-
- Preprint server copy:
- 10.1101/2023.06.16.23291523
Authors
+ Wellcome Trust
More from this funder
- Funder identifier:
- https://ror.org/029chgv08
- Grant:
- 216421/Z/19/Z
+ National Institute for Health and Care Research
More from this funder
- Funder identifier:
- https://ror.org/0187kwz08
- Grant:
- CL-2022-13-005
- MIC-2016-018
- NIHR300105
- Preprint server:
- medRxiv
- Publication date:
- 2023-06-19
- DOI:
- Language:
-
English
- Keywords:
- Pubs id:
-
1469181
- Local pid:
-
pubs:1469181
- Deposit date:
-
2026-05-29
- ARK identifier:
Terms of use
- Copyright holder:
- Dorward et al
- Copyright date:
- 2023
- Rights statement:
- ©2023 The Authors. The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record